Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is taking its cardiovascular risk assessment solutions directly to the employer benefits market by participating in four national benefits conferences in June. The company is targeting organizations responsible for employee benefits, which are increasingly seeking strategies to identify cardiovascular risk earlier and manage associated healthcare costs.
Cardiovascular disease remains one of the most expensive health conditions in the United States. According to the American Heart Association, direct cardiovascular healthcare costs accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any major diagnostic group. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses.
Cardio Diagnostics has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By engaging directly with stakeholders at these conferences, the company hopes to demonstrate how its approach can help employers reduce the financial burden of cardiovascular disease.
The conferences provide a platform for Cardio Diagnostics to discuss innovative approaches to cardiovascular disease prevention, risk assessment and cost management. The company’s solutions are positioned as a way for employers to proactively address one of the leading drivers of healthcare spending.
For more information on the latest news and updates relating to CDIO, visit the company’s newsroom at https://nnw.fm/CDIO.
This news matters because cardiovascular disease is a significant cost driver for employers and the healthcare system. By identifying risk earlier, employers can implement preventive measures that may reduce the incidence of major cardiovascular events, leading to lower medical costs and improved employee productivity. The potential impact is substantial given the high prevalence and cost of cardiovascular disease in the U.S.
